A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Recruiting now · Phase 3 · Has a placebo group
Conditions studied: Juvenile Psoriatic Arthritis
In brief
The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.
Key facts
- Study ID
- NCT06869551
- Run by
- Bristol-Myers Squibb
- People needed
- 60
- Starts
- 2025-03-13
- Expected to finish
- 2031-03-04
- Last updated by the study team
- 2026-06-26
Who can join
Age: 5 and older, up to 17. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA).
- Participants must have at least three joints that are affected by arthritis.
- Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems.
You may not qualify if…
- Participants must not have been diagnosed with JPsA before 5 years of age.
- Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA,
- Participants must not have a history of chronic eye inflammation (uveitis), or were diagnosed with uveitis within the last three months.
- Other protocol-defined Inclusion/Exclusion criteria apply.
Where it is running
- Guangzhou Women and Children's Medical Center — Guangzhou, Guangdong, China (enrolling)
- Childrens Hospital of Nanjing Medical University — Nanjing, Jiangsu, China (enrolling)
- The First Hospital of Jilin University — Changchun, Jilin, China (enrolling)
- The Children's Hospital of Zhejiang University School of Medicine — Hangzhou, Zhejiang, China (enrolling)
- Children's Hospital of Fudan University — Shanghai, China (enrolling)
- Fakultni nemocnice Olomouc — Olomouc, Olomouc Region, Czechia (enrolling)
- Fakultni nemocnice v Motole — Prague, Praha 5, Czechia (enrolling)
- Kinderklinik des Uni-Klinikums Erlangen — Erlangen, Germany (enrolling)
- Praxis Kinder- und Jugendrheumatologie Dr. Ivan Foeldvari — Hamburg, Germany (enrolling)
- University of Naples Federico II — Naples, Campania, Italy (enrolling)
- Azienda Ospedaliera Universitaria Meyer IRCCS — Florence, Tuscany, Italy (enrolling)
- Centro de Oncologia Leonardo Da Vinci - ATO Terapias — Fortaleza, Ceará, Brazil (enrolling)
- Spitalul Clinic de Urgenta pentru Copii Cluj-Napoca — Cluj-Napoca, Cluj, Romania (enrolling)
- University Multiprofile Hospital for Active Treatment "Sveti Georgi" EAD — Plovdiv, Bulgaria (enrolling)
- Sc Medaudio-Optica Srl — Râmnicu Vâlcea, Vâlcea County, Romania (enrolling)
- Hospital Universitari Vall d'Hebron — Barcelona, Barcelona [Barcelona], Spain (enrolling)
- Hospital Universitario Ramón y Cajal — Madrid, Madrid, Comunidad de, Spain (enrolling)
- Hospital Universitari i Politecnic La Fe — Valencia, Spain (enrolling)
- Istanbul Universitesi Cerrahpasa — Istanbul- Fatih, Istanbul, Turkey (Türkiye) (enrolling)
- LMK Serviços Médicos S/S — Porto Alegre, Rio Grande do Sul, Brazil (enrolling)
- Santa Casa de Misericordia de Belo Horizonte — Belo Horizonte, Minas Gerais, Brazil (enrolling)
- Umraniye Training and Research Hospital — Istanbul, Turkey (Türkiye) (enrolling)
- Hospital Das Clinicas Ufpe — Recife, Pernambuco, Brazil (enrolling)
- Santa Casa Instituto de Pesquisa — São Paulo, Brazil (enrolling)
- The Children's Hospital of Chongqing Medical University — Chongqing, Chongqing Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.